GLP-1 and Kidney Health: FLOW Trial Data and FDA Approval
The FLOW trial: landmark evidence for kidney health
If you have been diagnosed with chronic kidney disease (CKD) alongside type 2 diabetes, you may have felt that your options were limited. High blood pressure medications, blood sugar control, and careful management have been the standard approach. But the research landscape changed in 2024 when the New England Journal of Medicine published results from the FLOW trial[1].
For the first time, a GLP-1 medication demonstrated significant protection against kidney disease progression. The benefit was strong enough that the FDA approved semaglutide in May 2024 specifically for reducing the risk of kidney disease progression in adults with type 2 diabetes and CKD. This was the first GLP-1 medication to receive this indication.
If you fall into this population, this matters. Here is what the trial showed and what it means for your situation.
What the FLOW trial actually found
The FLOW trial enrolled 3,533 adults with type 2 diabetes and chronic kidney disease (stages 3a through 4, meaning reduced kidney function but not yet kidney failure)[1]. Participants were randomized to receive either semaglutide 1 mg weekly (a different dose than the weight loss formulations) or placebo, alongside standard kidney disease care.
The primary composite endpoint measured whether participants experienced kidney disease progression (defined as a 40% decline in eGFR, kidney failure requiring dialysis or transplant, or kidney-related death) OR death from any cardiovascular or kidney cause.
Over an average follow-up of 3.1 years, semaglutide reduced the risk of this composite endpoint by 24% compared to placebo[1]. The hazard ratio was 0.76 (95% confidence interval 0.66 to 0.88, p less than 0.001). This means the benefit was not a chance finding. The trial was stopped early because the benefit was so clear that continuing to give placebo to the control group was considered unethical.
The secondary outcomes reinforced the benefit: semaglutide reduced the rate of kidney disease progression specifically (eGFR decline) and reduced cardiovascular death, heart attack, or stroke by 18% compared to placebo[1].
This was not just mechanistic evidence or surrogate markers. This was hard clinical outcomes: prevented kidney failure, prevented kidney-related death, prevented progression of kidney disease.
How GLP-1 medications protect kidney health
The kidney is a highly vascularized organ with specialized cells that filter waste from your blood. When you have diabetes and metabolic dysfunction, your kidneys face sustained stress: high blood sugar damages the delicate filtering structures, high blood pressure strains the blood vessels in the kidney, and chronic inflammation accelerates kidney disease progression.
GLP-1 medications appear to protect the kidney through multiple mechanisms working in parallel.
Blood pressure reduction. GLP-1 medications reduce blood pressure, particularly systolic pressure. High blood pressure is a major driver of kidney disease progression. Lower blood pressure translates directly to less stress on the kidney’s filtering units, called nephrons. This is one of the largest mechanisms of kidney protection.
Better blood sugar control. High blood sugar is toxic to kidney tissue. It drives inflammation and damages the basement membrane of the glomeruli (the filtering structures). GLP-1 medications lower blood glucose levels, which reduces this direct cellular damage.
Weight loss and metabolic improvement. Losing weight reduces the metabolic burden on your kidneys. Your kidneys have to filter waste products from your whole body. When you are carrying excess weight, particularly visceral fat, your kidneys face higher workload and more inflammatory signals. Weight loss reduces both the mechanical and metabolic stress.
Direct kidney receptor activity. GLP-1 receptors are expressed in kidney tubular cells and the glomeruli themselves. When activated, these receptors trigger anti-inflammatory signaling and reduce the production of harmful proteins that drive kidney scarring.
Anti-inflammatory effects. Chronic kidney disease is fundamentally an inflammatory process. As your kidneys lose function, they release inflammatory signals that accelerate further damage. GLP-1 medications have direct anti-inflammatory effects that slow this cascade.
The mechanism is multifactorial. Blood pressure control, glucose control, weight loss, direct receptor effects, and anti-inflammatory benefits all contribute to the kidney protection observed in the FLOW trial.
Earlier kidney protection evidence
The FLOW trial is the most recent and largest kidney outcomes trial for a GLP-1 medication, but kidney protection from GLP-1 therapy is not new.
The LEADER trial, published in 2016, examined liraglutide (a different GLP-1 agonist) in patients with type 2 diabetes[2]. While primarily a cardiovascular outcomes trial, LEADER also measured kidney outcomes. Liraglutide reduced the rate of decline in kidney function (eGFR) and reduced the development of microalbuminuria (excess protein in urine, an early sign of kidney disease).
The SUSTAIN-6 trial studied semaglutide in people with type 2 diabetes and found improvements in kidney biomarkers and reduced rates of progression to kidney failure[3].
The pattern across multiple GLP-1 medications and multiple studies suggests that kidney protection is a class effect, not specific to one drug or one trial. The FLOW trial was specifically designed to study kidney outcomes directly, which is why it provides the most robust evidence.
Who this matters for
You should think carefully about kidney health and GLP-1 treatment if any of these apply to you:
You have type 2 diabetes and chronic kidney disease. This is the population where the evidence is strongest. If you have been diagnosed with CKD (stages 3a, 3b, or 4) and you also have type 2 diabetes, semaglutide now has FDA approval for reducing the risk of kidney disease progression. Your provider should discuss this option with you as part of your kidney disease management plan.
You have microalbuminuria or elevated albumin in urine. This is an early sign of kidney damage, even if your eGFR (estimated glomerular filtration rate) is still normal. GLP-1 medications reduce albuminuria in patients with diabetes.
You have metabolic syndrome or obesity with metabolic risk factors. Even if you do not yet have diagnosed CKD, the metabolic improvements from GLP-1 treatment protect your kidney health as a secondary benefit. Better blood pressure, better glucose control, and weight loss all reduce your risk of developing kidney disease.
You have type 2 diabetes without CKD. Preventing kidney disease is just as important as treating it once it develops. If you have diabetes, you are at risk for CKD. GLP-1 medications reduce this risk.
Your provider will review your kidney function labs (eGFR, creatinine, urine protein) as part of your baseline evaluation for any weight management program. If your kidney function is reduced, your provider will discuss whether GLP-1 treatment is medically appropriate for your situation and monitor your kidney function periodically as you start treatment.
Important distinction: branded semaglutide versus compounded semaglutide
Here is something critical that many patients do not hear clearly: The FLOW trial evidence and the FDA approval for kidney disease protection are specific to brand-name, FDA-approved semaglutide prescribed for type 2 diabetes.
Compounded semaglutide has not been evaluated in kidney outcomes trials. While the active ingredient is the same, the kidney protection evidence is specific to the branded product. Compounded medications are prepared by licensed compounding pharmacies and are not FDA-approved products. They have not undergone independent FDA evaluation for safety, efficacy, or quality.
This matters because if kidney disease prevention or progression management is a significant factor in your decision to start GLP-1 treatment, this is a conversation to have explicitly with your provider. The clinical evidence supporting kidney disease protection is specific to the brand-name, FDA-approved formulation prescribed for type 2 diabetes in patients with CKD.
If you have CKD and are specifically seeking treatment for kidney protection, your provider should discuss whether the branded product is appropriate for your situation.
Tirzepatide and kidney outcomes
Tirzepatide is a newer GLP-1/GIP receptor agonist. The kidney outcome evidence for tirzepatide is not yet as robust as for semaglutide.
The SURMOUNT-1 trial (the primary weight loss trial for tirzepatide) included kidney biomarkers as secondary endpoints. Tirzepatide showed improvements in eGFR and reductions in albuminuria in patients with obesity, some of whom had diabetes or CKD. These are positive signals, but they are biomarker improvements, not clinical outcomes.
A dedicated kidney outcomes trial for tirzepatide, similar to FLOW, has not been published as of 2026. The broader metabolic benefits of tirzepatide (blood pressure reduction, glucose control, weight loss) are expected to benefit kidney health indirectly. But the level of evidence is stronger for semaglutide.
If kidney disease management is your primary concern, your provider may recommend semaglutide specifically because the clinical outcomes evidence is more complete. This is not to say tirzepatide will not help your kidneys, but the randomized trial evidence showing kidney disease protection is more mature for semaglutide.
What GLP-1 treatment requires: provider evaluation and monitoring
GLP-1 medications are not contraindicated in kidney disease, but they are also not a “plug and play” treatment. Your provider needs to evaluate your specific situation.
Here is what your provider will do before starting you on a GLP-1 program:
Review your kidney function labs. Your provider will request recent eGFR, serum creatinine, and urinalysis. Depending on your kidney function and other factors, your provider will determine whether GLP-1 treatment is appropriate. Most patients with CKD can safely take GLP-1 medications, but dosing, monitoring frequency, and choice of medication may need adjustment.
Assess your overall health context. Some patients with very advanced kidney disease (stage 5, requiring dialysis) or other specific conditions may need special consideration. Your provider will review whether GLP-1 treatment fits with your other medical conditions and medications.
Check blood pressure and blood sugar control. GLP-1 medications lower both. If you are already on blood pressure or diabetes medications, these may need to be adjusted as your GLP-1 starts working.
Plan for monitoring. Most GLP-1 programs that include patients with CKD will recheck kidney function labs at 3 months and then periodically (every 6 months or annually). You should expect improvement in kidney biomarkers over time, particularly if you are losing weight and your blood pressure and blood sugar are improving.
Some patients have asked whether GLP-1 medications stress the kidneys or cause kidney injury. The research shows the opposite. Kidney function improves or stabilizes with GLP-1 treatment, particularly semaglutide. This is not a treatment that requires you to “sacrifice” one aspect of your health for another.
What kidney protection does not mean
GLP-1 medications are not a replacement for other kidney disease treatments or management strategies. If you have diabetes or high blood pressure, you likely need medications for those conditions. Those medications remain essential.
GLP-1 medications are an addition to your overall kidney disease management strategy, not a substitute for it. The FLOW trial was conducted alongside standard kidney disease care. That care includes blood pressure control, blood sugar management, and often other medications like ACE inhibitors or ARBs (which have kidney-protective effects of their own).
Also important: the kidney protection takes time to develop. The FLOW trial measured outcomes over an average of 3.1 years. You will not see dramatic improvement in your eGFR after one month. The benefit accumulates over time. What you may see more quickly is stabilization of kidney function (your eGFR stops declining as rapidly) and improvements in albuminuria (less protein in your urine).
Finally: GLP-1 medications are one tool in your kidney health strategy. They work best when combined with lifestyle modifications (lower sodium intake, hydration, exercise) and consistent medication adherence. Your provider and care team will help you integrate this into a comprehensive approach to protecting your kidneys.
The path forward: what to discuss with your provider
If you have type 2 diabetes and CKD, or if you have diabetes and are concerned about preventing kidney disease, here are the conversations to have:
-
Know your kidney numbers. Get a recent eGFR and creatinine level. Ask your provider what these numbers mean for your kidney stage and your risk of progression.
-
Ask about the FLOW trial. If you have type 2 diabetes and CKD, ask your provider whether semaglutide is appropriate for you based on the FLOW trial evidence. This is a legitimate clinical indication that your provider should discuss.
-
Understand your GLP-1 options. If your provider recommends a GLP-1 medication, ask about branded versus compounded options and how the evidence differs between them.
-
Plan for monitoring. If you start a GLP-1 program, ask how often your kidney function will be monitored and what improvements you should expect to see.
-
Combine medication with lifestyle. Ask your provider for guidance on diet (sodium intake, protein intake for your specific situation), hydration, and exercise. GLP-1 medications work best as part of a comprehensive approach.
What the evidence means for your decision
The FLOW trial evidence is strong. Semaglutide reduces the risk of kidney disease progression by 24% in patients with type 2 diabetes and CKD. This was not a small benefit in a select subgroup. This was a large trial across diverse populations, and the trial was stopped early because the benefit was overwhelming.
The FDA approval of semaglutide for kidney disease progression signals that this is now a legitimate clinical indication, not just a side benefit of weight loss. If you have type 2 diabetes and CKD, your provider should discuss this option with you as part of your kidney disease management plan.
At the same time, the evidence is specific to the branded product studied in the trial. Compounded semaglutide may offer metabolic benefits (weight loss, blood pressure reduction, blood sugar improvement) that are secondarily protective for your kidneys, but this is different from having FDA-approved, clinically-proven kidney disease protection.
The key is getting your kidney numbers, understanding your kidney stage, and having an honest conversation with your provider about which treatment option makes sense for your specific situation. That is how you make the best decision for your long-term kidney health.
Important: Compounded medications are not FDA-approved products. They are prepared by US-based, state-licensed compounding pharmacies and have not been independently evaluated by the FDA for safety, efficacy, or quality. Brand-name GLP-1 medications approved for kidney disease indications are different products from compounded semaglutide, and Transformation Health is not affiliated with the manufacturers of those branded products. All prescriptions require evaluation by an independent, licensed healthcare provider. Not all patients will qualify. Results vary by individual.
Citations
[1] Perkovic V et al. “Semaglutide and Renal Outcomes in Type 2 Diabetes (FLOW Trial).” New England Journal of Medicine. 2024;390(15):1379-1395. https://pubmed.ncbi.nlm.nih.gov/38785209/
[2] Marso SP et al. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” New England Journal of Medicine. 2016;375(4):311-322. https://pubmed.ncbi.nlm.nih.gov/27295427/
[3] Marso SP et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” New England Journal of Medicine. 2016;375(19):1834-1844. https://pubmed.ncbi.nlm.nih.gov/27633186/